Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 04, 2026, titled "Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Phase 3 Study of Masupirdine in Alzheimer's Disease Agitation at 50% study completers Study to Continue Unchanged".